Sage Journals: Discover world-class research

Abstract

Purpose:

To investigate the impact of antioxidant treatment and genetic risk on the development of intermediate age-related macular degeneration (AMD) in patients without baseline AMD, using data from the Age-Related Eye Disease Study (AREDS) Cataract Trial.

Methods:

Genetic risk and antioxidant treatment were analyzed as independent and interacting risk factors for the development of intermediate AMD in 554 AREDS individuals for whom genotyping was available. Genetic risk was determined using an allele dosage model based on the total number of complement factor H and age-related maculopathy sensitivity 2 risk alleles.

Results:

Overall, 14% of patients developed intermediate AMD over approximately 8 years. The risk of developing intermediate AMD varied from 6.5% for patients with 0 risk alleles to 39% for those with 3 or 4 risk alleles (P < .0001). Antioxidants had no impact on the development of intermediate AMD overall. However, antioxidant treatment had a significant impact on progression to intermediate AMD for patients with low or high genetic risk. Patients with 0 or 1 risk alleles had increased risk of progression to intermediate AMD (hazard ratio [HR] = 2.31, P = .017) if treated with antioxidants compared to placebo. Patients with 3 or 4 risk alleles had decreased risk of progression to intermediate AMD (HR = 0.27, P = .0008) if treated with antioxidants compared to placebo.

Conclusion:

On average, antioxidant treatment has no impact on the development of intermediate AMD in patients without AMD. However, antioxidant treatment may increase the risk of developing intermediate AMD in patients with low genetic risk and may reduce the risk of developing intermediate AMD in patients with high genetic risk. Since patients with high genetic risk have the greatest risk of progressing from intermediate to advanced AMD, genotype-directed antioxidant treatment of patients without AMD may ultimately lead to fewer cases of advanced AMD.

Keywords

Get full access to this article

View all access options for this article.

References

Fletcher

Bentham

Agnew

. Sunlight exposure, antioxidants, and age-related macular degeneration. Arch Ophthalmol. 2008;126(10):1396–1403.

Yong

Scott

Greenberg

. Ocular nutritional supplements: are their ingredients and manufacturers’ claims evidence-based? Ophthalmology. 2015;122(3):595–599.

Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417–1436.

Chew

Clemons

SanGiovanni

. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology. 2012;119(11):2282–2289.

Awh

Hawken

Zanke

. Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study. Ophthalmology. 2015;122(1):162–169.

Klein

Francis

Rosner

. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology. 2008;115(6):1019–1025.

Seddon

Reynolds

Daly

Rosner

. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology. 2011;118(11):2203–2211.

Awh

Lane

Hawken

Zanke

Kim

. Author reply. Ophthalmology. 2014;121(8):e39.

Chew

Klein

Clemons

; Age-Related Eye Disease Study Research Group. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology. 2014;121(11):2173–2180.

10.

Chew

Klein

Clemons

Agrón

Abecasis

. Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test? Ophthalmology. 2015;122(1):212–215.

11.

Awh

Zanke

Re: Chew et al.: genetic testing in persons with age-related macular degeneration and the use of AREDS supplements: to test or not to test? (Ophthalmology 2015;122:212-215). Ophthalmology. 2015;122(10):e62–e63.

12.

Awh

Zanke

. Re: Chew et al.: no clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 (Ophthalmology 2014;121:2173-2180). Ophthalmology. 2015;122(8):e46.

13.

Seddon

Silver

Rosner

. Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis [Published online July 28, 2016]. Br J Ophthalmol. 2016. pii: bjophthalmol–2016-308624.

14.

Wang

Buitendijk

Rochtchina

. Genetic susceptibility, dietary antioxidants, and long-term incidence of age-related macular degeneration in two populations. Ophthalmology. 2014;121(3):667–675.

15.

Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol. 2001;119(10):1439–1452.

16.

Fritsche

Igl

Bailey

. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48(2):134–143.

17.

Awh

Lane

Hawken

Zanke

Kim

. CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology. 2013;120(11):2317–2323.

18.

Atmaca-Sonmez

Othman

. CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet. 2006;38(9):1049–1054.

19.

1000 Genomes Project Consortium; Abecasis

Auton

Brooks

, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56–65.

20.

Maller

George

Purcell

. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet. 2006;38(9):1055–1059.

21.

van Leeuwen

Witteman

. Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and omega-3 fatty acids: the Rotterdam study. Arch Ophthalmol. 2011;129(6):758–766.

22.

Shiotani

Murao

Fujita

. Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding. J Gastroenterol Hepatol. 2014;29(suppl 4):47–52.

23.

Clemons

Rankin

McBee

; Age-Related Eye Disease Study Research Group. Cognitive impairment in the Age-Related Eye Disease Study: AREDS report no. 16. Arch Ophthalmol. 2006;124(4):537–543.

24.

Williams

McKay

Carson

Craig

Silvestri

Passmore

. Age-related macular degeneration-associated genes in Alzheimer disease. Am J Geriatr Psychiatry. 2015;23(12):1290–1296.

25.

Liu

Kanekiyo

. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–118.

26.

Klein

Myers

Meuer

. Risk alleles in CFH and ARMS2 and the long-term natural history of age-related macular degeneration: the Beaver Dam Eye Study. JAMA Ophthalmol. 2013;131(3):383–392.

Progression From No AMD to Intermediate AMD as Influenced by Antioxidant Treatment and Genetic Risk

Abstract

Purpose:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References